OrganOx Metra® New Enrollment Post-Approval Study
OrganOx Metra® New Enrollment Post-Approval Study
The objective of the OrganOx metra® New Enrollment Post-Approval Study is to collect data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on the OrganOx according to the current indications for use in the real-world setting.
The OrganOx metra® New Enrollment Post-Approval Study is a multi-site, single arm, unblinded post-approval study that will enroll deceased DBD or DCD donor liver and adult liver transplant recipients according to the current indication and that match the eligibility criteria below.
Inclusion Criteria:
Exclusion Criteria:
Subject requiring all of the following at the time of transplantation:
Subject has acute/fulminant liver failure (UNOS status 1A)
Subject planned to undergo simultaneous transplantation of more than one organ (e.g., liver and kidney) from the same liver donor
Subject is pregnant (as confirmed by urine or serum pregnancy test) or nursing
Concurrent enrollment in another clinical study. Subjects enrolled in clinical studies or registries where only measurements and/or samples are taken (no test device or test drug) are allowed to participate.